Sanofi And Regeneron Rekindle Their Alliance, But Will Magic Strike Again?
The drugmakers’ decades-long R&D affair is back on, but the relationship hasn’t always been smooth sailing and along with one exceptional winner, the partnership also delivered disappointments.
Scrip - October 1, 2026

Deal Watch: AbbVie Looks To Iambic, Valkai For AI Discovery And Development Help
Plus deals involving Rohto/PharmBio, Chugai/InxMed, Genentech/Earendil, Roche/Atavistik, Boehringer Ingelheim/Envisagenics and more.
Scrip - October 1, 2026

Taiho Draws From Hypomethylating Agent Experience In ASTX030 Program
The company said it plans to file for approval of the azacitidine/cedazuridine combination pill in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Scrip - October 1, 2026

Lilly Reinforces Its Lead In Obesity, But There’s Still Room For New Arrivals
The US pharma giant’s winning streak continues but analysts are sure room remains in the obesity market for further innovation and new market entrants
Scrip - October 1, 2026

Scrip’s Guide To October 2026: ESMO, Q3s and Novel Anti-Infectives Approvals
October will bring plenty of oncology data from the ESMO meeting, while the Q3 reporting season gets underway, plus approval decisions are expected for a number of new anti-infectives.
Scrip - October 1, 2026

Regeneron, Sanofi Extend Dupixent Playbook With Four Next-Gen Immunology Antibodies
The expanded alliance sets the stage for a new wave of immunology assets as Sanofi and Regeneron look beyond Dupixent for future growth.
Scrip - October 1, 2026

Pfizer’s Phase II Atopic Dermatitis Data Push Tilrekimig Into Pivotal AD, Asthma Trials
Mid-stage data presented at EADV support the targeting of IL-13, IL-4 and TSLP with Pfizer’s trispecific antibody, which the firm has moved into Phase III studies in two indications, including a head-to-head trial versus Sanofi’s IL-13/IL4 inhibitor Dupixent.
Scrip - October 1, 2026

FDA Adds BD, Current Health And Skribe Medical To READI-Home Innovation Challenge
The FDA selected three more technologies for its READI-Home Innovation Challenge, including home blood collection from Becton Dickinson, AI-based CRS monitoring from Current Health and a wearable cardiac monitoring system from Skribe Medical. The initiative aims to reduce hospital readmissions.
Medtech Insight - October 1, 2026

Longevity Medicine’s Best-Evidenced Tools Are The Least Glamorous, CoreCare CEO Says
CoreCare CEO and longevity medicine doctor Hillary Lin said that the evidence backing testing for hypertension and diabetes, heart scans and healthy lifestyle choices is among the strongest in longevity care, while whole-body MRIs and early cancer diagnostics come with caveats.
Medtech Insight - October 1, 2026

Execs On The Move: September 21–25, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - October 1, 2026

Abu Dhabi Bets On Screening And Diagnosis To Help Set The Gulf’s Fertility Benchmark
Abu Dhabi has set a 2030 roadmap to achieve ambitious global reproductive health ecosystem goals. Prevention and preconception health, genetic screening, fertility diagnosis and treatment and IVF are central elements. L.E.K. Consulting explained how Abu Dhabi is differentiating in its approach.
Medtech Insight - October 1, 2026

GLP-1s And CGMs Have High Untapped Combination Potential, Dexcom Says
State of Type 2 report shows the scale of the non-insulin market Dexcom wants to tap as it pushes for wider Medicare CGM reimbursement.
Medtech Insight - October 1, 2026

Brands Must Guide, Monitor Influencer and Media Claims – NAD Panel
Attorneys at NAD's 'Ad Law in Motion' conference in New York said that, under NAD’s definition of advertising, a brand can be held to claims made in influencer posts, press releases and interviews.
HBW Insight - October 2, 2026

ACNU Switches Have No ‘Moving Goalposts’ As FDA, Industry Gain Knowledge About Final Rule
“Now that we are trying to complete and devise some efforts about how to follow those requirements, it's sometimes being perceived as moving the goalposts,” says ONPD director Karen Murry.
HBW Insight - October 2, 2026

Samsung Bioepis And Teva Take Over The World With Multi-Product Biosimilar Deal
Samsung Bioepis and Teva deepen their partnership with a third development and commercialization deal – this time going global with six potential assets.
Generics Bulletin - October 1, 2026

Fresenius Secures Its Biosimilars Future With €750m mAbxience Buyout
Fresenius has taken full control of biosimilars developer mAbxience, striking a deal worth up to €750m to buy out the remaining 45% of the company, in a move that reflects both the increasing significance of biosimilars to Fresenius as well as the benefits of vertical integration.
Generics Bulletin - October 1, 2026

‘We Believe We Can Play A Larger Role’ – Orifarm Chief On ‘Ambitious’ Generics Expansion Plans
Orifarm has today unveiled a five-year plan that will see it push into new markets across Europe, with a “significant expansion in generics.” Chief executive Mads Fink Eriksen spoke to Generics Bulletin to offer further insights into the Danish firm’s strategy.
Generics Bulletin - October 1, 2026

Fresenius Kabi Adds Direct-To-Payer Biosimilar Route With Waltz
Fresenius Kabi has added a direct-to-payer channel for three US biosimilars through Waltz Health, as the group also expands European IV fluids manufacturing with €54m of investment in Poland and Italy.
Generics Bulletin - October 1, 2026

What’s Next? Five Things To Look Out For In October
Generics Bulletin previews the most noteworthy and anticipated events for October 2026.
Generics Bulletin - October 1, 2026

Gilead’s Duty-To-Innovate Win: What The HIV Drug Ruling Means For Pharma Lifecycle Strategy
California's top court refused to hold Gilead liable for delaying a safer HIV drug to protect its franchise – a win for industry. But a parallel Canadian case, and a live split over what it means for lifecycle strategy, leave the duty-to-innovate question unsettled.
In Vivo - October 2, 2026